Two New Drugs for Sickle Cell Disease

Two drugs, voxelotor (Oxbryta) and crizanlizumab-tmca (Adakveo), have been approved to treat sickle cell disease.The most common adverse effects of voxelotor are diarrhea, headache, abdominal pain, nausea, fatigue, rash, and fever. Hypersensitivity reactions are also possible.The most common adverse effects of crizanlizumab-tmca are back pain, nausea, fever, and arthralgia. Serious adverse effects include infusion-related reactions and interference with automated platelet counts.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research